Figure 5. Elevated FoxM1 expression predicted poor survival in breast cancer patients, especially in the ER(+), PR(+) subgroups and BC patients received adjuvant chemotherapy only or treated with tamoxifen only.

(A) FoxM1 mRNA level was significantly associated with RFS in all BC patients. (B–C) FoxM1 mRNA expression was correlated to RFS in BC patients with ER (+) and PR (+) tumors. (D) High mRNA level of FoxM1 was significantly associated with shorter RFS in BC patients who have received chemotherapy adjuvant only. (E–F) High mRNA level of FoxM1 was significantly associated with shorter RFS in ER (+) subgroup of BC patients who have received chemotherapy adjuvant only but not in ER (−) BC patients. (G–H) High mRNA level of FoxM1 was significantly associated with shorter RFS in BC patients who have received therapies that include or exclude endocrine therapy. (I) High mRNA level of FoxM1 was associated with shorter RFS in BC patients who have received tamoxifen only sub-group.